用于检测和治疗 CRC 的工程菌治疗学。
Engineered bacterial therapeutics for detecting and treating CRC.
机构信息
Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA, USA; Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
出版信息
Trends Cancer. 2024 Jul;10(7):588-597. doi: 10.1016/j.trecan.2024.04.001. Epub 2024 Apr 30.
Despite an overall decrease in occurrence, colorectal cancer (CRC) remains the third most common cause of cancer deaths in the USA. Detection of CRC is difficult in high-risk groups, including those with genetic predispositions, with disease traits, or from certain demographics. There is emerging interest in using engineered bacteria to identify early CRC development, monitor changes in the adenoma and CRC microenvironment, and prevent cancer progression. Novel genetic circuits for cancer therapeutics or functions to enhance existing treatment modalities have been tested and verified in vitro and in vivo. Inclusion of biocontainment measures would prepare strains to meet therapeutic standards. Thus, engineered bacteria present an opportunity for detection and treatment of CRC lesions in a highly sensitive and specific manner.
尽管总体发病率有所下降，但结直肠癌（CRC）仍然是美国第三大常见癌症死因。在高危人群中，包括有遗传易感性、疾病特征或来自特定人群的人群中，CRC 的检测较为困难。人们对利用工程细菌来识别早期 CRC 发展、监测腺瘤和 CRC 微环境变化以及预防癌症进展越来越感兴趣。新型癌症治疗基因回路或增强现有治疗模式的功能已在体外和体内进行了测试和验证。包含生物遏制措施将使菌株能够达到治疗标准。因此，工程细菌为以高度敏感和特异的方式检测和治疗 CRC 病变提供了机会。
Zotero 插件